TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06717815
Drug: IPG11406
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Medical Products:~IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.
Study: NCT06143891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Table-Route of administration:oral
Study: NCT06143891
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study: NCT06749457
Drug: AZD7760
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD7760 as a single intravenous infusion.
Study: NCT06714123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets similar in size and color
Study: NCT06753071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet, twice daily, for 3 months
Study: NCT06782139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
Study: NCT06660173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection.
Study: NCT05417594
Drug: AZD9574
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD9574 orally.
Study: NCT05417594
Drug: [11C]AZ1419 3391
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive \[11C\]AZ1419 3391 intravenously.
Study: NCT06751602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily)
Study: NCT06222827
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo prefilled syringe is identical in composition to satralizumab, but does not contain the satralizumab active agent. It is identical in appearance and packaging to satralizumab. During the first period (double blind period), placebo will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
Study: NCT06008756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matched to enlicitide decanoate taken by mouth.
Study: NCT06564623
Drug: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatment on Day 1, 8, 15 and 22 of cycle 1 and on day 1 of remaining cycles (C2-C4) in Prime Phase. In the Boost Phase - every 2 cycles (8 weeks) beginning from C6D1.
Study: NCT05649748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
Study: NCT06659341
Drug: BAY3498264
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04734418
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min
Study: NCT06375304
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention consists of prescribing B/F/TAF to eligible ART-experienced migrant patients, free of charge, in four care settings, for 12 months (48 weeks).~B/F/TAF is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements.
Study: NCT06127043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via SC
Study: NCT05711615
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05711615
Drug: Peposertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06253663
Drug: KTE-X19
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single infusion of chimeric antigen receptor (CAR) T cells
Study: NCT06253663
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT06362226
Drug: Steroid/Antibiotic (Maxitrol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group one subjects receive topical maxitrol ophthalmic ointment twice daily for two weeks
Study: NCT06362226
Drug: 5-FU/Kenalog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group two undergoes treatment with a subcutaneous injection of a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination (80/20 ratio, 0.3-0.5 mL per session) administered in four sessions, spaced two weeks apart, starting within 48 hours of hospital presentation
Study: NCT05098574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
Study: NCT05422365
Drug: Intravenous immunoglobulin (IVIG), 10% solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
Study: NCT04433741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously
Study: NCT05808946
Drug: Sepsis Supportive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
Study: NCT05750056
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
Study: NCT05750056
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentail 0.1 ug/kg was administered for sedation induction.
Study: NCT05898672
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of rosuvastatin tablets
Study: NCT05129280
Drug: RO7444973
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.
Study: NCT06313502
Drug: 75gm HDAA
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 75gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 120 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.
Study: NCT06313502
Drug: 125gm HDAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 125gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 240 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.
Study: NCT04336046
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: using 1 mg /kg normal saline
Study: NCT05479097
Drug: Anti-Hypertensive
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
Study: NCT06067100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are administered placebo
Study: NCT06017609
Drug: Placebo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching in appearance to the active drug capsules
Study: NCT04202406
Drug: Acetaminophen and codeine and caffeine
Normalized name: acetaminophen / caffeine / codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
Study: NCT04202406
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
Study: NCT04202406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive placebo (starch) 1hour before treatment.
Study: NCT06605651
Drug: 0.9% NaCl solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three intra-articular injections during and/or following DAIR procedure
Study: NCT06660823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive placebo in form of inert starch tablet
Study: NCT06658054
Drug: Adjuvant analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.
Study: NCT06660329
Drug: Janus Kinase Inhibitor
Normalized name: Janus kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.
Study: NCT06661018
Drug: Coenzyme Q 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks
Study: NCT06661018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
Study: NCT06608238
Drug: D-MNA 200 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-MNA , (doxorubicin) patch, 200 mcg
Study: NCT06608238
Drug: D-MNA 100 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-MNA (doxorubicin) patch, 100 mcg
Study: NCT04726592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV
Study: NCT04726592
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 100 mg IV
Study: NCT06660784
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depending on the indication, the subjects will be given NO treatment or not. In ECMO assisted mechanical ventilation + NO treatment group, the subjects will be randomly assigned to NO treatment via ventilator or membrane oxygenator.
Study: NCT06660992
Drug: HSK31858, tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis
Study: NCT06660992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo comparator of study
Study: NCT06657859
Drug: GLM101
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLM101 IV infusion
Study: NCT06660498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
Study: NCT05422534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo or CoQ10/day for 12 weeks
Study: NCT06527144
Drug: 3mg TQC3721 Suspension for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3721 suspension for inhalation is target inhibitor.
Study: NCT06527144
Drug: 6mg TQC3721 Suspension for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3721 suspension for inhalation is target inhibitor.
Study: NCT06527144
Drug: Placebo TQC3721 suspension for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without active drug substance.
Study: NCT05858853
Drug: Recombinant Human Serum Albumin
Normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
Study: NCT05858853
Drug: Recombinant Human Serum Albumin
Normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
Study: NCT05049213
Drug: Carrageenan nasal spray and 1% PVP- mouthwash and gargle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day1 to Day7~1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time~2. Oral gargling 3 times/day, 15cc/per time
Study: NCT04673942
Drug: Checkpoint Inhibitor, Immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
Study: NCT05609877
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline will be administered intravenously instead of pre-procedure analgesia.
Study: NCT05609877
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 0.5-1.0 mcg/kg will be administered intravenously as pre-procedure analgesia
Study: NCT06481371
Drug: zuojinwan
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.
Study: NCT05058612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose PO/NG 18h
Study: NCT05148442
Drug: IBI322
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-human CD47/PD-L1 bispecific antibody
Study: NCT04554966
Drug: Placebo for ABBV-382
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT06046612
Drug: Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.
Study: NCT06084754
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin IV injection 1gm divided 250mg every 6hours
Study: NCT05825430
Drug: general anaesthetic technique only
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
Study: NCT05069714
Drug: MTX-hold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary discontinuation of methotrexate for 1 or 2 weeks
Study: NCT05021367
Drug: TQB3823 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.
Study: NCT05191888
Drug: Vonoprazan, Amoxicillin and Clarithromycin
Normalized name: vonoprazan, amoxicillin and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day vonoprazan triple therapy
Study: NCT05191888
Drug: Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14th Rabeprazole reverse mixed therapy
Study: NCT05220319
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
Study: NCT04727632
Drug: [18F]Fluoroestradiol (FES) PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]Fluoroestradiol (FES) PET/CT
Study: NCT06405737
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to receive intranasal administration of placebo (24 IU).
Study: NCT05749666
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone taken daily according to preset tapering protocol
Study: NCT05803161
Drug: Congrong Runtong oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola
Study: NCT05803161
Drug: Placental Congrong Runtong oral liquid
Normalized name: human placental tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placental Congrong Runtong oral liquid
Study: NCT04971239
Drug: topical methotrexate micoemulsion
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
Study: NCT05295784
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
Study: NCT05397041
Drug: BMB-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one of several different oral doses of BMB-101 once or twice daily
Study: NCT05397041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo
Study: NCT06341296
Drug: LV
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/m\^2, d1, 14 days per cycle, 8 cycles.
Study: NCT03686306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk.
Study: NCT05727800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration.
Study: NCT04710550
Drug: F18-3F4AP
Normalized name: fluorodeoxyglucose F18
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET Scan
Study: NCT04975919
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04738357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05099055
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
Study: NCT04748757
Drug: recombinant human annexin A5
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant human annexin A5, manufactured as SY-005
Study: NCT04748757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 50 ml
Study: NCT05025098
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle.
Study: NCT05025098
Drug: Precision therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision therapy for both AML and MDS patients is standard therapy + tumor board determined precision therapy. The tumor board determined precision therapy can be all available drugs with a marketing authorization in Norway.